Targeting p53 as a general tumor antigen - PubMed (original) (raw)
Targeting p53 as a general tumor antigen
M Theobald et al. Proc Natl Acad Sci U S A. 1995.
Abstract
A major barrier to the design of immunotherapeutics and vaccines for cancer is the idiosyncratic nature of many tumor antigens and the possibility that T cells may be tolerant of broadly distributed antigens. We have devised an experimental strategy that exploits species differences in protein sequences to circumvent tolerance of high-affinity T cells. HLA transgenic mice were used to obtain cytotoxic T lymphocytes specific for peptides from the human p53 tumor-suppressor molecule presented in association with HLA-A2.1. Although such p53-specific cytotoxic T cells did not recognize nontransformed human cells, they were able to lyse a wide variety of human tumor cells lines, thus confirming the existence of broadly distributed determinants that may serve as targets for immunotherapy.
Similar articles
- The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire.
Hernández J, Lee PP, Davis MM, Sherman LA. Hernández J, et al. J Immunol. 2000 Jan 15;164(2):596-602. doi: 10.4049/jimmunol.164.2.596. J Immunol. 2000. PMID: 10623800 - The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
Yu Z, Liu X, McCarty TM, Diamond DJ, Ellenhorn JD. Yu Z, et al. J Surg Res. 1997 May;69(2):337-43. doi: 10.1006/jsre.1997.5058. J Surg Res. 1997. PMID: 9224403 - Targeting p53, hdm2, and CD19: vaccination and immunologic strategies.
Voss RH, Lotz C, Cellary A, Theobald M. Voss RH, et al. Bone Marrow Transplant. 2000 May;25 Suppl 2:S43-5. doi: 10.1038/sj.bmt.1702353. Bone Marrow Transplant. 2000. PMID: 10933187 Review. - p53: a potential target antigen for immunotherapy of cancer.
Offringa R, Vierboom MP, van der Burg SH, Erdile L, Melief CJ. Offringa R, et al. Ann N Y Acad Sci. 2000 Jun;910:223-33; discussion 233-6. doi: 10.1111/j.1749-6632.2000.tb06711.x. Ann N Y Acad Sci. 2000. PMID: 10911916 Review.
Cited by
- Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
Moore TV, Lyons GE, Brasic N, Roszkowski JJ, Voelkl S, Mackensen A, Kast WM, Le Poole IC, Nishimura MI. Moore TV, et al. Cancer Immunol Immunother. 2009 May;58(5):719-28. doi: 10.1007/s00262-008-0594-2. Epub 2008 Oct 3. Cancer Immunol Immunother. 2009. PMID: 18836717 Free PMC article. - Molecular alterations in pediatric sarcomas: potential targets for immunotherapy.
Goletz TJ, Mackall CL, Berzofsky JA, Helman LJ. Goletz TJ, et al. Sarcoma. 1998;2(2):77-87. doi: 10.1080/13577149878037. Sarcoma. 1998. PMID: 18521238 Free PMC article. - The mutational status of p53 can influence its recognition by human T-cells.
Shamalov K, Levy SN, Horovitz-Fried M, Cohen CJ. Shamalov K, et al. Oncoimmunology. 2017 Jan 31;6(4):e1285990. doi: 10.1080/2162402X.2017.1285990. eCollection 2017. Oncoimmunology. 2017. PMID: 28507791 Free PMC article. - Raising the bar: the curative potential of human cancer immunotherapy.
Rosenberg SA. Rosenberg SA. Sci Transl Med. 2012 Mar 28;4(127):127ps8. doi: 10.1126/scitranslmed.3003634. Sci Transl Med. 2012. PMID: 22461638 Free PMC article. Review. - Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.
DeLeo AB, Whiteside TL. DeLeo AB, et al. Expert Rev Vaccines. 2008 Sep;7(7):1031-40. doi: 10.1586/14760584.7.7.1031. Expert Rev Vaccines. 2008. PMID: 18767952 Free PMC article. Review.
References
- Cancer Immunol Immunother. 1993 Oct;37(5):329-36 - PubMed
- Cell. 1993 Sep 10;74(5):929-37 - PubMed
- J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):121-6 - PubMed
- Cell. 1994 Feb 25;76(4):593-6 - PubMed
- Cell. 1994 Feb 25;76(4):651-63 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous